Cardiovascular-kidney-metabolic disease risk factors—encompassing heart disease, kidney disease, diabetes, and obesity—can be detected in children as young as 8 years old, according to a study published in Nature Metabolism. Researchers at UTHealth Houston analyzed 5,000 proteins from a community cohort and verified their findings across tens of thousands of adult patients, revealing that these early biological signatures are surprisingly modifiable.
Detecting Cardiometabolic Risk Signatures in Childhood
The journey toward chronic illness often begins much earlier than standard medical checkups capture. Investigators utilized a group of 273 children participating in the Border Health Research Cohort at the UTHealth Houston School of Public Health in Brownsville. By examining 5,000 proteins in the blood, the team mapped six distinct protein signatures that heavily influence a person’s likelihood of developing cardiovascular-kidney-metabolic disease later in life.
Crucially, these exact same protein markers appeared in 685 adults from the same Brownsville community who already faced high risks of irreversible disease, according to the research team. Senior authors Joseph McCormick, MD, professor of epidemiology and James H. Steele, DVM, Professor at the School of Public Health, along with Susan Fisher-Hoch, MD, professor of epidemiology, established the Cameron County segment of the cohort back in 2014.
“The cohort provides key silent markers of chronic disease traits that are manifest in adults, including some parents of the children, with clinical disease. These children have generously participated in the study at our Clinical Research Unit in Brownsville,” McCormick stated.
Fisher-Hoch praised the local workforce that made the detailed biological mapping possible. “Nearly 20 staff, recruited from the same community and provided appropriate skills, did the hard work of conducting the detailed study of the children in our clinical research unit and laboratory. The community-based team is immensely proud of the contribution of their efforts to human health,” Fisher-Hoch noted.
Validating Proteomic Signatures Across International Populations
To ensure the discovered protein markers held universal predictive power, the research team checked their models against outside populations. Led by first author Heather Highland, PhD, assistant professor of epidemiology at the School of Public Health, the group evaluated disease outcomes among more than 28,000 adults enrolled in the UK Biobank, a large-scale prospective study tracking over 500,000 residents in the UK.
Individuals within the UK Biobank who shared these specific protein patterns faced a markedly higher threat of suffering a heart attack or other severe health complications linked to cardiovascular-kidney-metabolic disease. These circulating proteins act as early warning lights across the body’s systems.
“Understanding the development of cardiovascular-kidney-metabolic disease across the lifecourse is critical,” Highland explained. “Proteins circulating in the blood can serve as markers of nascent pathologies across the body. These early markers can help identify people at greater risk for increased monitoring and potentially early intervention.”
Reversing Disease Trajectories With GLP-1 Drugs
While discovering early risk markers changes how physicians might screen patients, the most striking revelation involves how easily those markers can shift. When the team cross-referenced their protein signatures with outcomes from GLP-1 drug trials, they discovered that the vast majority of high-risk proteins found in adults facing irreversible disease actually changed course when patients took GLP-1 drugs.
This discovery reframes chronic cardiometabolic decline from an unchangeable genetic fate into a manageable condition. Kari North, PhD, director of the Border Health Research Center and professor at the School of Public Health, served as the corresponding author for the study published under doi: 10.1038/s42255-026-01589-7.
“This association is really one of the most exciting messages, because those proteins that predict the risk of cardiometabolic diseases all moved in a healthy direction after these adults took GLP-1. This makes this a modifiable risk state rather than a fixed marker of fate,”
North added that the window of opportunity opens long before adulthood sets in. “Childhood is the time that we really need to start intervening because it’s reversible,”
North emphasized.
Shifting Toward Pediatric Precision Medicine and Screening
Many pediatric participants in the Brownsville cohort already displayed physical traits tied to cardiovascular-kidney-metabolic disease, such as elevated body weight, altered liver function tests, abnormal cholesterol numbers, and insulin resistance. Yet, the advanced blood assays used by the UTHealth Houston researchers go far beyond standard pediatric checkups.
The findings advocate for a fundamental upgrade in pediatric screening protocols and a pivot toward precision medicine. Catching hidden protein dysregulations early allows healthcare systems to alter a child’s health trajectory before irreversible damage occurs.
“The dysregulation of the proteins that influence risk of heart attack later in life, if we can reverse them in childhood, then we can really make a huge dent in the cardiovascular disease burden that we see in adult populations around the world today,”
“We need to do better screening in children, and if we see children who are at an elevated risk, the time to act is now,”
North concluded.
Related reading
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications.
- Pink Noise Boosts Brain Waste Clearance During Sleep
- Tennessee Schools Shift to Virtual Learning and Early Dismissal Due to Extreme Heat (news-usa.today)
- China’s spy agency warns of AI risk to national security (newsylist.com)
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.